Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
Status:
Completed
Trial end date:
2018-01-28
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of PR013 topical ophthalmic drops (0.045% and 0.06%)
compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
using a modified Conjunctival Allergen Challenge Model (Ora-CAC®).